P-cadherin inhibitor PCA062

Drug Overview

P-cadherin inhibitor PCA062 (also known as PCA-062) is an investigational, humanized antibody-drug conjugate (ADC) designed to target and inhibit P-cadherin (placental cadherin; CDH3). It consists of a high-affinity anti-P-cadherin monoclonal antibody linked to the potent cytotoxic maytansinoid payload DM1 via a non-cleavable SMCC linker.

In the clinical landscape of March 2026, PCA062 is primarily recognized for its historical role as a “first-in-class” candidate that demonstrated the potential of targeting the cadherin family via an ADC approach. P-cadherin is a cell-surface glycoprotein that is overexpressed in various solid tumors—including triple-negative breast cancer (TNBC), esophageal squamous cell carcinoma (ESCC), and head and neck squamous cell carcinoma (HNSCC)—while having limited expression in normal adult tissues. This differential expression makes it an attractive target for delivering cytotoxic payloads directly to malignant cells. However, following clinical evaluation, it was determined that the single-agent activity of PCA062 was insufficient at tolerable doses, leading to the termination of its primary development program.

• Generic Name: P-cadherin inhibitor PCA062.
• Code Names: PCA062, PCA-062.
• Drug Class: Antibody-Drug Conjugate (ADC); P-cadherin Antagonist.
• Mechanism: Binding to P-cadherin on the tumor cell surface, followed by internalization and lysosomal release of the DM1 payload to induce mitotic arrest.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Discontinued/Investigational. As of March 2026, PCA062 is not FDA-approved. Novartis terminated its Phase 1 clinical development in 2018 due to limited clinical activity at the Maximum Tolerated Dose (MTD).

What Is It and How Does It Work? (Mechanism of Action)

PCA062 utilizes the “Trojan horse” strategy of antibody-drug conjugates to deliver a lethal dose of chemotherapy specifically to cells expressing P-cadherin.

1. Targeted Binding

P-cadherin is a calcium-dependent adhesion molecule involved in cell-to-cell contact. In many epithelial cancers, its overexpression promotes tumor cell motility, invasion, and proliferation.

• Specific Recognition: PCA062 binds to a unique epitope in the extracellular EC1 domain of the P-cadherin protein.
• Selective Delivery: The antibody serves as a delivery vehicle, ignoring P-cadherin-negative cells and seeking out tumors with high P-cadherin density.

2. Internalization and Lysis

Once the ADC binds to the P-cadherin receptor, the entire complex is pulled inside the cell through a process called endocytosis.

• Lysosomal Trafficking: The complex is transported to the lysosomes (the cell’s “waste disposal” centers).
• Payload Release: In the lysosome, the antibody is degraded, releasing the DM1 (mertansine) payload into the cell’s cytoplasm.

3. Mitotic Arrest

DM1 is a potent tubulin inhibitor.

• Microtubule Disruption: It prevents the formation of the mitotic spindle, the structure cells use to pull DNA apart during division.
• Apoptosis: Unable to complete cell division, the cancer cell enters “mitotic arrest” and eventually undergoes apoptosis (programmed cell death).

Clinical Research and Status (2026 Update)

While the original monotherapy trials have concluded, the data from PCA062 continues to inform 2026 research in cadherin-targeted therapies.

• Phase 1 Trial (NCT02375958): This first-in-human study evaluated 47 patients with P-cadherin-positive solid tumors. While the drug was stable in the blood and showed a manageable safety profile, only one patient (with head and neck cancer) achieved a partial response.
• Termination Rationale: Because higher doses—which might have improved efficacy—were expected to cause significant toxicity, Novartis terminated development before the dose-expansion phase.
• Next-Generation Research (2024–2026): Researchers are now using the lessons from PCA062 to develop bispecific ADCs (targeting both P-cadherin and CDH17) and radionuclide theranostics (like⁹⁰Y-FF-21101) to achieve better tumor penetration and cell-killing power.

Dosage and Safety Profile (Historical Data)

The following parameters were established during the Phase 1 dose-escalation studies:

Common Side Effects:

• Hematologic: Thrombocytopenia and neutropenia (low white blood cells).
• Gastrointestinal: Nausea and diarrhea.
• General: Fatigue and decreased appetite.
• Note: No toxicities specifically related to the targeting of P-cadherin in normal tissues were identified, suggesting the antibody itself was highly specific.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, P-cadherin is studied for its role in the “epithelial-to-mesenchymal transition” (EMT). Researchers use PCA062 as a laboratory tool to observe how inhibiting P-cadherin affects the Cancer Stem Cell niche and tumor invasion. In 2026, there is also focus on “Internalization Engineering,” where scientists are using the crystal structure of PCA062 to design new antibodies that can be “pulled” into cells more efficiently, a critical step for successful ADC therapy.

Patient Management and Practical Recommendations

For Patients in Ongoing Cadherin-Directed Trials:

• Biomarker Testing: Screening for P-cadherin (CDH3) expression via Immunohistochemistry (IHC) or genomic sequencing is typically mandatory for enrollment.
• Platelet Monitoring: Regular blood tests are essential to monitor for thrombocytopenia, especially if the drug uses a maytansinoid (DM1/DM4) payload.

“Do’s and Don’ts” List:

• DO report any unusual bruising or bleeding immediately; these are signs of low platelets.
• DO ask your oncology team about “bispecific” options if you are P-cadherin positive but failed initial therapy.
• DON’T assume all cadherin inhibitors are the same; E-cadherin and P-cadherin have very different roles in cancer, and drugs are not interchangeable.
• DON’T ignore signs of severe fatigue, as this can be a side effect of the cytotoxic payload release.

Legal Disclaimer

The information provided is for educational and historical purposes only and does not constitute medical advice. PCA062 is an investigational agent and is not approved by the U.S. FDA for commercial use. Clinical development of this specific molecule has been terminated. Always consult with a board-certified oncologist regarding currently approved ADCs (such as Enhertu or Kadcyla) and eligibility for new clinical trials.